375

ADJUVANT CHEMOTHERAPY IS NOT ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA WITH PERSISTENT LYMPHOVASCULAR INVASION OR LYMPH NODE INVOLVEMENT AFTER NEOADJUVANT CHEMOTHERAPY

Date
May 19, 2024

Introduction
The role of adjuvant chemotherapy (AC) after neoadjuvant treatment (NAT) for patients with pancreatic ductal adenocarcinoma (PDAC) is not well-defined. The aim of this study is to determine the impact of AC on overall survival (OS) for patients with persistent lymphovascular invasion (LVI) and lymph node (LN) involvement after NAT.
Methods
Patients with stage I-III PDAC who underwent surgical resection at US hospitals reporting to the National Cancer Database from 2010 to 2020 were identified. A multilevel, mixed-effects Cox multivariable regression model was used to assess for adjusted between-group differences in OS. An interaction term between LVI or LN involvement and AC use was utilized to test the potential benefit of the selective use of AC in patients after NAT. Landmark analyses set at 6-months were performed to minimize immortal time bias.

Results
A total of 47,896 patients were included; group A (LVI-, LN-) had 12,570 patients, group B (LVI+, LN-) 3,767, group C (LVI-, LN+) 11,093, and group D (LVI+, LN+) 20,466. Median OS differed significantly between groups, with group A having the most favorable survival (37.2 months), followed by group B (26.7 months), group C (22.7 months), and group D (18.6 months, p<0.01). A total of 7,445 patients received NAT, of whom 2,781 (37.4%) received AT. On multivariable analysis, the interaction term for LVI or LN involvement and AC in patients who had NAT was not associated with OS (group A, HR 0.96, p=0.47; group B and C, HR 1.05, p=0.57; group D, HR 0.99, p=0.89).

Conclusions
LVI and LN involvement are independently associated with worse OS in patients with resected PDAC. After NAT, the use of AC in patients with persistent LVI and LN involvement was not associated with improved OS. The incongruency in these findings between “real-world” data and institutional series should be an impetus for future clinical trials to be conducted to better inform clinicians on how to appropriately select patients for additional cytotoxic but potentially efficacious AC after NAT.
Kaplan-Meier curves comparing those who received adjuvant chemotherapy to those who received no adjuvant chemotherapy.

Kaplan-Meier curves comparing those who received adjuvant chemotherapy to those who received no adjuvant chemotherapy.


Tracks

Related Products

Thumbnail for THE PERFECT STORM: LAPAROSCOPIC TRANSCHOLEDOCHAL BILE DUCT EXPLORATION FOR BILE DUCT BEZOAR IN ADVANCED CIRRHOSIS WITH PORTAL HYPERTENSION
THE PERFECT STORM: LAPAROSCOPIC TRANSCHOLEDOCHAL BILE DUCT EXPLORATION FOR BILE DUCT BEZOAR IN ADVANCED CIRRHOSIS WITH PORTAL HYPERTENSION
Transcholedochal laparoscopic bile duct exploration is a challenging procedure. Advanced cirrhosis with portal hypertension is associated with unique set of challenges not limited to increased risk of bleeding and fragile liver…
Thumbnail for ROBOTIC ANATOMICAL RIGHT HEPATECTOMY FOR NECROTIC CHOLANGIOCARCINOMA
TECHNIQUE OF INFLOW CONTROL IN NAKAMURA TYPE B PORTAL VEIN ANATOMY
ROBOTIC ANATOMICAL RIGHT HEPATECTOMY FOR NECROTIC CHOLANGIOCARCINOMA TECHNIQUE OF INFLOW CONTROL IN NAKAMURA TYPE B PORTAL VEIN ANATOMY
Anatomical variations in the inflow vasculatures must be anticipated in any anatomical hepatectomy to avoid complications. Nakamura Type B portal vein (PV) anatomy requires individual isolation of right anterior and posterior PV to avoid narrowing of the left PV…
Thumbnail for USE OF DEEP LEARNING TO EVALUATE TUMOR MORPHOLOGICAL FEATURES FOR PREDICTION OF COLON CANCER RECURRENCE
USE OF DEEP LEARNING TO EVALUATE TUMOR MORPHOLOGICAL FEATURES FOR PREDICTION OF COLON CANCER RECURRENCE
BACKGROUND/AIM: Current pathologic assessment of colorectal cancer (CRC) does not account for tumor heterogeneity, yet biologically important signals are embedded in morphologic differences that can drive patient prognosis…
Thumbnail for ROBOTIC PANCREATICODUODENECTOMY (PD) FOR OBSTRUCTING AMPULLARY MASS
ROBOTIC PANCREATICODUODENECTOMY (PD) FOR OBSTRUCTING AMPULLARY MASS
This video depicts a robotic PD performed on a 69-year-old male presenting with flu-like